$AVTX
Avalo Therapeutics, Inc. Stock $avtx

$avtx Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-K Financial Statement

#000162828017002566 Filed on March 14, 2017

Income Statement

Concept	2017 Q1	2016 Q4	2015 Q4
Revenue	$384.2K	$182.0K	$0.00
YoY Change
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$384.2K
YoY Change
Gross Profit Margin	100.0%
Selling, General & Admin	$1.330M	$1.090M	$1.920M
YoY Change	-49.8%	-43.23%	22.29%
% of Gross Profit	346.24%
Research & Development	$953.1K	$773.0K	$1.751M
YoY Change	-58.44%	-55.85%	-22.52%
% of Gross Profit	248.06%
Depreciation & Amortization	$5.830K	$10.00K	$0.00
YoY Change	-14.11%		-100.0%
% of Gross Profit	1.52%
Operating Expenses	$2.283M	$773.0K	$1.751M
YoY Change	-0.42%	-55.85%	-54.28%
Operating Profit	-$1.899M
YoY Change	-61.57%
Interest Expense	-$57.75K	-$83.00K	-$158.0K
YoY Change	-61.76%	-47.47%	-112.06%
% of Operating Profit
Other Income/Expense, Net	-$61.51K
YoY Change	-68.88%
Pretax Income	-$1.960M	-$1.640M	-$3.650M
YoY Change	-61.87%	-55.07%	44.84%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$1.961M	-$1.639M	-$3.648M
YoY Change	-61.86%	-55.07%	-136.44%
Net Earnings / Revenue	-510.31%	-900.55%
Basic Earnings Per Share	-$0.19
Diluted Earnings Per Share	-$0.19	-$2.12	-$5.07
COMMON SHARES
Basic Shares Outstanding	10.74M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q4	2015 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.000M	$5.130M	$21.16M
YoY Change	-81.93%	-75.76%	80.24%
Cash & Equivalents	$3.002M	$5.128M	$21.16M
Short-Term Investments
Other Short-Term Assets	$270.0K	$400.0K	$460.0K
YoY Change	-6.9%	-13.04%	9.52%
Inventory		$0.00
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$3.459M	$5.663M	$21.62M
YoY Change	-79.52%	-73.81%	77.82%
LONG-TERM ASSETS
Property, Plant & Equipment	$39.21K	$43.24K	$35.22K
YoY Change	-1.97%	22.79%	-11.96%
Goodwill		$0.00
YoY Change
Intangibles		$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$60.00K	$60.00K	$0.00
YoY Change			-100.0%
Total Long-Term Assets	$102.0K	$106.1K	$35.22K
YoY Change	155.12%	201.2%	-77.99%
TOTAL ASSETS
Total Short-Term Assets	$3.459M	$5.663M	$21.62M
Total Long-Term Assets	$102.0K	$106.1K	$35.22K
Total Assets	$3.561M	$5.769M	$21.66M
YoY Change	-78.97%	-73.36%	75.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$595.9K	$1.010M	$678.1K
YoY Change	1.0%	48.97%	-27.09%
Accrued Expenses	$640.0K	$940.0K	$1.890M
YoY Change	-70.23%	-50.26%	92.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.492M	$2.354M	$3.208M
YoY Change	-54.78%	-26.63%	67.96%
Total Short-Term Liabilities	$2.737M	$4.312M	$5.850M
YoY Change	-55.65%	-26.29%	17.23%
LONG-TERM LIABILITIES
Long-Term Debt	$1.492M	$0.00	$2.353M
YoY Change	0.16%	-100.0%	-55.68%
Other Long-Term Liabilities	$1.250M	$0.00	$370.5K
YoY Change	220.51%	-100.0%
Total Long-Term Liabilities	$1.492M	$0.00	$2.724M
YoY Change	-20.62%	-100.0%	-48.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.737M	$4.312M	$5.850M
Total Long-Term Liabilities	$1.492M	$0.00	$2.724M
Total Liabilities	$3.987M	$5.562M	$8.574M
YoY Change	-50.48%	-35.13%	-16.76%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.00M	-$70.04M	-$53.56M
YoY Change		30.75%
Common Stock	$10.90K	$9.434K	$8.650K
YoY Change		9.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$425.8K	$207.0K	$13.08M
YoY Change
Total Liabilities & Shareholders Equity	$3.561M	$5.769M	$21.66M
YoY Change	-78.97%	-73.36%	75.79%

Cashflow Statement

Concept	2017 Q1	2016 Q4	2015 Q4
OPERATING ACTIVITIES
Net Income	-$1.961M	-$1.639M	-$3.648M
YoY Change	-61.86%	-55.07%	-136.44%
Depreciation, Depletion And Amortization	$5.830K	$10.00K	$0.00
YoY Change	-14.11%		-100.0%
Cash From Operating Activities	-$2.236M	-$3.710M	-$3.540M
YoY Change	-39.72%	4.8%	-10.83%
INVESTING ACTIVITIES
Capital Expenditures	$1.801K	$0.00	$0.00
YoY Change	-79.76%
Acquisitions	$0.00
YoY Change
Other Investing Activities	$0.00
YoY Change
Cash From Investing Activities	-$1.801K	$0.00	$0.00
YoY Change	-81.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.187M
YoY Change
Debt Paid & Issued, Net	$874.7K
YoY Change	8.81%
Cash From Financing Activities	$121.0K	30.00K	21.40M
YoY Change	-114.4%	-99.86%	-107100.0%
NET CHANGE
Cash From Operating Activities	-$2.236M	-3.710M	-3.540M
Cash From Investing Activities	-$1.801K	0.000	0.000
Cash From Financing Activities	$121.0K	30.00K	21.40M
Net Change In Cash	-$2.117M	-3.680M	17.86M
YoY Change	-53.57%	-120.6%	-547.62%
FREE CASH FLOW
Cash From Operating Activities	-$2.236M	-$3.710M	-$3.540M
Capital Expenditures	$1.801K	$0.00	$0.00
Free Cash Flow	-$2.238M	-$3.710M	-$3.540M
YoY Change	-39.81%	4.8%	-10.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	253132	USD
CY2016Q4	cerc	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	160116	USD
CY2015Q1	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	535000	USD
CY2015Q4	cerc	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	1885458	USD
CY2016Q4	cerc	Accrued Liabilities And Other Current Liabilities AccruedLiabilitiesAndOtherCurrentLiabilities	942435	USD
CY2015Q4	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	464719	USD
CY2016Q4	cerc	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	315937	USD
CY2014	cerc	Adjustments To Additional Paid In Capital Issuance Of Temporary Equity AdjustmentsToAdditionalPaidInCapitalIssuanceOfTemporaryEquity	54107	USD
CY2014	cerc	Adjustments To Additional Paid In Capital Reclassification From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationFromLiabilityToEquity	426303	USD
CY2014	cerc	Allocation Of Debt And Equity Proceeds To Investor Rights Obligation AllocationOfDebtAndEquityProceedsToInvestorRightsObligation	2598510	USD
CY2015	cerc	Allocation Of Debt And Equity Proceeds To Investor Rights Obligation AllocationOfDebtAndEquityProceedsToInvestorRightsObligation	0	USD
CY2016	cerc	Allocation Of Debt And Equity Proceeds To Investor Rights Obligation AllocationOfDebtAndEquityProceedsToInvestorRightsObligation	0	USD
CY2016Q4	cerc	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2015Q4	cerc	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	207157	USD
CY2016Q4	cerc	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	6174163	USD
CY2015	cerc	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0002
CY2016	cerc	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0002
CY2015	cerc	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.0426
CY2016	cerc	Effective Income Tax Rate Reconciliation Warrants EffectiveIncomeTaxRateReconciliationWarrants	0.0015
CY2016Q4	cerc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Recognized In Next Twelve Months EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRecognizedInNextTwelveMonths	815654	USD
CY2016Q4	cerc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Recognized Year Four EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRecognizedYearFour	108716	USD
CY2016Q4	cerc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Recognized Year Three EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRecognizedYearThree	357279	USD
CY2016Q4	cerc	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Recognized Year Two EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostRecognizedYearTwo	766151	USD
CY2014	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-2266161	USD
CY2015Q2	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-198000	USD
CY2015Q3	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-1465000	USD
CY2015Q4	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-185000	USD
CY2015	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-1313049	USD
CY2016Q1	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	47000	USD
CY2016Q2	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-91000	USD
CY2016Q3	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	101000	USD
CY2016Q4	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-130000	USD
CY2016	cerc	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-72625	USD
CY2015	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	classofstock
CY2016	cerc	Fair Value Measurements Changes In Valuation Techniques Number FairValueMeasurementsChangesInValuationTechniquesNumber	0	classofstock
CY2014	cerc	Increase Decreasein Grant Receivable IncreaseDecreaseinGrantReceivable	0	USD
CY2015	cerc	Increase Decreasein Grant Receivable IncreaseDecreaseinGrantReceivable	0	USD
CY2016	cerc	Increase Decreasein Grant Receivable IncreaseDecreaseinGrantReceivable	132472	USD
CY2014	cerc	Increase In Equity Due To Modification Of Temporary Equity And Issuance Of Common Stock Dividends IncreaseInEquityDueToModificationOfTemporaryEquityAndIssuanceOfCommonStockDividends	6004611	USD
CY2015Q4	cerc	Number Of Class Of Stock Authorized NumberOfClassOfStockAuthorized	2	classofstock
CY2015	cerc	Number Of Material Adjustments To Prior Period Estimates Of Accrued Expenses NumberOfMaterialAdjustmentsToPriorPeriodEstimatesOfAccruedExpenses	0	classofstock
CY2016	cerc	Number Of Material Adjustments To Prior Period Estimates Of Accrued Expenses NumberOfMaterialAdjustmentsToPriorPeriodEstimatesOfAccruedExpenses	0	classofstock
CY2014	cerc	Payment Of Fractional Shares Upon Conversion Of Preferred Stock To Common Stock PaymentOfFractionalSharesUponConversionOfPreferredStockToCommonStock	0	USD
CY2015	cerc	Payment Of Fractional Shares Upon Conversion Of Preferred Stock To Common Stock PaymentOfFractionalSharesUponConversionOfPreferredStockToCommonStock	1373	USD
CY2016	cerc	Payment Of Fractional Shares Upon Conversion Of Preferred Stock To Common Stock PaymentOfFractionalSharesUponConversionOfPreferredStockToCommonStock	0	USD
CY2014	cerc	Payments Of Stock Issuance Costs Excluding Amounts Paid To Underwriters PaymentsOfStockIssuanceCostsExcludingAmountsPaidToUnderwriters	365253	USD
CY2015	cerc	Payments Of Stock Issuance Costs Excluding Amounts Paid To Underwriters PaymentsOfStockIssuanceCostsExcludingAmountsPaidToUnderwriters	2269171	USD
CY2016	cerc	Payments Of Stock Issuance Costs Excluding Amounts Paid To Underwriters PaymentsOfStockIssuanceCostsExcludingAmountsPaidToUnderwriters	114945	USD
CY2013Q3	cerc	Restricted Cash Estimated Annual Reduction RestrictedCashEstimatedAnnualReduction	58000	USD
CY2013	cerc	Period Of Abatement PeriodOfAbatement	P3M
CY2014	cerc	Reclassification Of Common Stock Warrants From Liability To Equity ReclassificationOfCommonStockWarrantsFromLiabilityToEquity	426303	USD
CY2015	cerc	Reclassification Of Common Stock Warrants From Liability To Equity ReclassificationOfCommonStockWarrantsFromLiabilityToEquity	0	USD
CY2016	cerc	Reclassification Of Common Stock Warrants From Liability To Equity ReclassificationOfCommonStockWarrantsFromLiabilityToEquity	0	USD
CY2016	cerc	Restricted Cash Number Of Periods Annual Reduction Permitted RestrictedCashNumberOfPeriodsAnnualReductionPermitted	P3Y
CY2013Q3	cerc	Security Deposit Required At End Of Lease Term SecurityDepositRequiredAtEndOfLeaseTerm	13000	USD
CY2015Q4	cerc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	1467886	USD
CY2016Q4	cerc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	2155234	USD
CY2016	cerc	Share Based Compensation Arrangement By Share Based Payment Award Share Reserve Increase As Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent	0.04
CY2014	cerc	Temporary Equity Extinguishment Upon Modification Of Convertible Preferred Stock TemporaryEquityExtinguishmentUponModificationOfConvertiblePreferredStock	12534438	USD
CY2015	cerc	Temporary Equity Extinguishment Upon Modification Of Convertible Preferred Stock TemporaryEquityExtinguishmentUponModificationOfConvertiblePreferredStock	0	USD
CY2016	cerc	Temporary Equity Extinguishment Upon Modification Of Convertible Preferred Stock TemporaryEquityExtinguishmentUponModificationOfConvertiblePreferredStock	0	USD
CY2016Q3	cerc	Threshold Price Per Common Stock On Any Trading Day To Present Notice For Purchase Of Common Stock ThresholdPricePerCommonStockOnAnyTradingDayToPresentNoticeForPurchaseOfCommonStock	0.50
CY2015Q4	cerc	Unit Purchase Option Liability UnitPurchaseOptionLiability	50571	USD
CY2016Q4	cerc	Unit Purchase Option Liability UnitPurchaseOptionLiability	51	USD
CY2015Q4	cerc	Warrants Outstanding WarrantsOutstanding	27606	USD
CY2016Q4	cerc	Warrants Outstanding WarrantsOutstanding	5501	USD
CY2014	cerc	Write Off Of Deferred Stock Issuance Costs WriteOffOfDeferredStockIssuanceCosts	1064106	USD
CY2015	cerc	Write Off Of Deferred Stock Issuance Costs WriteOffOfDeferredStockIssuanceCosts	0	USD
CY2016	cerc	Write Off Of Deferred Stock Issuance Costs WriteOffOfDeferredStockIssuanceCosts	0	USD
CY2016	dei	Amendment Flag AmendmentFlag	false
CY2016	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2016	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2016	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
CY2016	dei	Document Period End Date DocumentPeriodEndDate	2016-12-31
CY2016	dei	Document Type DocumentType	10-K
CY2016	dei	Entity Central Index Key EntityCentralIndexKey	0001534120
CY2017Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10744959	shares
CY2016	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2016	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016Q4	dei	Entity Public Float EntityPublicFloat	6800000	USD
CY2016	dei	Entity Registrant Name EntityRegistrantName	Cerecor Inc.
CY2016	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2016	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	678109	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1010209	USD
CY2015Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	1885458	USD
CY2016Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	942435	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	60835	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	87691	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	66638557	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	70232651	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1086581	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	394748	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1694891	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	394748	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1694891	USD
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	625208	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2015Q4	us-gaap	Assets Assets	21657565	USD
CY2016Q4	us-gaap	Assets Assets	5768865	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	21622349	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	5662794	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3421480	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11742349	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21161967	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5127958	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	8320869	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9419618	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-16034009	USD
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8650143	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9434141	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8650143	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9434141	shares
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	8650	USD
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	9434	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	2249666	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2015Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5688256	USD
CY2016Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2374031	USD
CY2015Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	126700	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	20364	USD
CY2014	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2015	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2016	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	81832	USD
CY2015Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	5561556	USD
CY2016Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	2353667	USD
CY2015Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24326374	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	30874531	USD
CY2015Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20350451	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	20587955	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1814296	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1840505	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	438351	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	90936	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1500520	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2169070	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	15599	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	11902	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1636000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1703000	USD
CY2016Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1095000	USD
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.4608
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.3975
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0003
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0512
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0344
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24326374	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30874531	USD
CY2014	us-gaap	Depreciation Depreciation	28943	USD
CY2015	us-gaap	Depreciation Depreciation	23508	USD
CY2016	us-gaap	Depreciation Depreciation	26856	USD
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.48
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.98
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.48
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.06
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.53
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.71
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.59
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.87
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0269
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0218
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1128073	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	272601	USD
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2047800	USD
CY2015Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2015Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2016Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2014	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P6Y3M
CY2014	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-17806	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4875030	USD
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	761000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1016000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	722000	USD
CY2015Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1924000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4422764	USD
CY2016Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2649000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7083155	USD
CY2015Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	0	USD
CY2016Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	132472	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-708366	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-268709	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	332100	USD
CY2014	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-28400	USD
CY2015	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	1121054	USD
CY2016	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-119495	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-353973	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	41243	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-22047	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	498	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-116666	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	15107	USD
CY2014	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1206187	USD
CY2015Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-219000	USD
CY2015Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-219000	USD
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-197000	USD
CY2015Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-158000	USD
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-793205	USD
CY2016Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-151000	USD
CY2016Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-127000	USD
CY2016Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-104000	USD
CY2016Q4	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-83000	USD
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-464181	USD
CY2014	us-gaap	Interest Paid InterestPaid	173514	USD
CY2015	us-gaap	Interest Paid InterestPaid	568299	USD
CY2016	us-gaap	Interest Paid InterestPaid	348888	USD
CY2015Q4	us-gaap	Interest Payable Current InterestPayableCurrent	39534	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	193781	USD
CY2015Q4	us-gaap	Liabilities Liabilities	8573838	USD
CY2016Q4	us-gaap	Liabilities Liabilities	5561863	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21657565	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5768865	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5849818	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4311863	USD
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3208074	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	2353667	USD
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	2353482	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	23858720	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	19602982	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-1425988	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-19502	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-19984	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21165589	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1899987	USD
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.35
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y2M27D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y5M9D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y5M9D
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	401550	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	391253	USD
CY2014	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	23685270	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2003182	USD
CY2014	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	7390000	USD
CY2015	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2014	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	14584307	USD
CY2015	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2016	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
CY2014	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	2249666	USD
CY2015	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	USD
CY2016	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	0	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	96051	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	130934	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	35216	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43243	USD
CY2014	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1811744	USD
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	3314225	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12240535	USD
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1723000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1875000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1238000	USD
CY2015Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1751000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6587183	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2293000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2502000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4582000	USD
CY2016Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	773000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10149879	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	175000	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	58832	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	11111	USD
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	62828	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53563480	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70035083	USD
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	0	USD
CY2015Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	135319	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1300000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	915242	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.24
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	700000	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	28344157	USD
CY2014	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2015	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2016Q1	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2016Q2	us-gaap	Revenue From Grants RevenueFromGrants	650000	USD
CY2016Q3	us-gaap	Revenue From Grants RevenueFromGrants	321000	USD
CY2016Q4	us-gaap	Revenue From Grants RevenueFromGrants	182000	USD
CY2016	us-gaap	Revenue From Grants RevenueFromGrants	1152987	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1086581	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	394748	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1694891	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.700
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.700
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	791251	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.55
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	116928	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25071	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	523390	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.80
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.35
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	552726	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	959188	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1849359	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.17
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.68
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.57
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1849359	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.57
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.60
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.04
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.31
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-34883	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15518349	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-10163380	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-14573138	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-16055591	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-3238000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-2912000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-692000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-3648000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-10490103	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-5140000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-3524000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-6169000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-1639000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-16471603	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3521153	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10490103	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16471603	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1059974	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	519844	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-391556	USD
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-17115565	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-11009947	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-16080047	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	313561	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	154845	USD
CY2016Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	158716	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	142000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	142000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	370538	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1250000	USD
CY2014	us-gaap	Paid In Kind Interest PaidInKindInterest	989258	USD
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	293748	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	162270	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19502	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19984	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34883	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-17846675	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-26330664	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	13083727	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	207002	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6500000	USD
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	642052	shares
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2226023	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8830396	shares
CY2016	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company has no financial instruments with off‑balance sheet risk of loss.</font></div></div>
CY2016	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business</font></div><div style="line-height:120%;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cerecor Inc. (the “Company” or “Cerecor”) was incorporated on January 31, 2011 in Delaware. The Company is a clinical‑stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders. The Company’s operations since inception have been limited to organizing and staffing the Company, acquiring rights to and developing certain product candidates, business planning and raising capital.</font></div><div style="line-height:120%;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity - Going Concern</font></div><div style="line-height:120%;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Accordingly, the financial statements do not include any adjustments that might be necessary should the Company be unable to continue to fund its operations. The Company has not generated any product revenues and has not yet achieved profitable operations. There is no assurance that profitable operations will ever be achieved, and if achieved, could be sustained on a continuing basis.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred recurring operating losses since inception. For the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred a net loss of </font><font style="font-family:inherit;font-size:10pt;">$16.5 million</font><font style="font-family:inherit;font-size:10pt;"> and generated negative cash flows from operations of </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$70.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the clinical development of its product candidates, its preclinical programs, business development and its organizational infrastructure. The Company will require substantial additional financing to fund its operations and to continue to execute its strategy. To fully execute its business plan, the Company will need to complete certain research and development activities, have positive clinical trial results and obtain marketing approval for its product candidates, which may span many years, and may ultimately be unsuccessful. Any delays in completing these activities or negative clinical trial results could adversely impact the Company. The Company plans to meet its capital requirements primarily through further offerings of equity or debt securities, non-dilutive financing arrangements such as federal grants, collaboration agreements or out-licensing arrangements, and to explore strategic alternatives such as an acquisition, merger, or business combination. In the long term, the Company plans to meet its capital requirements through revenue from product sales to the extent its product candidates receive marketing approval and are commercialized. There can be no assurance, however, that the Company will be successful in obtaining financing at the level needed to sustain operations and develop its product candidates or on terms acceptable to the Company, that the Company's exploration of strategic alternatives will result in any such transaction, or that the Company will obtain approvals necessary to market its products or achieve profitability or sustainable, positive cash flow. If the Company fails to raise capital or enter into such arrangements or transactions in the short term, it will have to significantly delay, scale back or discontinue the development of one or more of its product candidates or cease its operations altogether. The Company currently anticipates that current cash and cash equivalents will be sufficient to meet its anticipated cash requirements well into the second quarter of 2017. These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that our financial statements were issued.</font></div></div>
CY2016	us-gaap	Revenue Recognition Deferred Revenue RevenueRecognitionDeferredRevenue	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Grant Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes grant revenue when there is (i) reasonable assurance of compliance with the conditions of the grant and (ii) reasonable assurance that the grant will be received. In April 2016, the Company received a research and development grant from the National Institute on Drug Abuse ("NIDA") at the National Institutes of Health ("NIH") to provide additional resources for the period of May 2016 through April 2017 for the Company’s now completed Phase 2 clinical trial for CERC-501, “</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior</font><font style="font-family:inherit;font-size:10pt;">.” The amount of the NIDA award was </font><font style="font-family:inherit;font-size:10pt;">$1.02 million</font><font style="font-family:inherit;font-size:10pt;">. Additionally, in July 2016, the Company received a research and development grant from the National Institute on Alcohol Abuse and Alcoholism ("NIAAA") at the NIH to provide additional resources for the period of July 2016 through June 2017 to progress the development of CERC-501 for the treatment of alcohol use disorder. The amount of the NIAAA award was </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company recognizes revenue under grants in earnings on a systemic basis in the period the related expenditures for which the grants are intended to compensate are incurred.</font></div></div>
CY2016	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-indent:84px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, other comprehensive income and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to clinical trial accruals, warrant liability and embedded derivative liabilities. The Company bases its estimates on historical experience and other market‑specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</font></div><div style="line-height:120%;text-indent:132px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to being a public company, the Company utilized estimates and assumptions in determining the fair value of its common stock as an input for determining the grant date fair value of stock option grants. Management used the assistance of a third‑party valuation firm in estimating the fair value of the common stock. The board of directors determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the historic prices at which the Company sold shares of its preferred stock.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-17-002566-index-headers.html	Edgar Link	pending
0001628280-17-002566-index.html	Edgar Link	pending
0001628280-17-002566.txt	Edgar Link	pending
0001628280-17-002566-xbrl.zip	Edgar Link	pending
cerc-20161231.xml	Edgar Link	completed
cerc-20161231.xsd	Edgar Link	pending
cerc-20161231_cal.xml	Edgar Link	unprocessable
cerc-20161231_def.xml	Edgar Link	unprocessable
cerc-20161231_lab.xml	Edgar Link	unprocessable
cerc-20161231_pre.xml	Edgar Link	unprocessable
cerc10-k20161231.htm	Edgar Link	pending
cercex-211.htm	Edgar Link	pending
cercex-231.htm	Edgar Link	pending
cercex-311.htm	Edgar Link	pending
cercex-312.htm	Edgar Link	pending
cercex-321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTX
Avalo Therapeutics, Inc. Stock $avtx

2017 Q1 Form 10-K Financial Statement

#000162828017002566 Filed on March 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX Avalo Therapeutics, Inc. Stock $avtx

2017 Q1 Form 10-K Financial Statement

#000162828017002566 Filed on March 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX
Avalo Therapeutics, Inc. Stock $avtx